Abstract 239P
Background
With the induction of molecular targeted therapy and immune checkpoint inhibitors, treatment strategies for systemic treatment of metastatic clear cell renal cell carcinoma (mCCRCC) have been changed with improved survival. However, for those patients diagnosed as metastatic non-clear cell renal cell carcinoma (mNCRCC), systemic therapy designed and approved for mCCRCC have been used because no validated systemic therapy exists. This retrospective study aimed to identify prognostic factors for patients with mNCRCC treated with systemic therapy.
Methods
A total of 270 patients were reviewed. Among them, 41 patients who pathologically diagnosed as mNCRCC and received systemic therapy were retrospectively analyzed. Clinical and pathological data were retrieved and analyzed retrospectively. The progression free survival (PFS) and overall survival (OS) between mNCRCC and mCCRCC patients were compared. The OS for patients with mNCRCC was further investigated with univariate and multivariate Cox’s proportional hazards regression models.
Results
After a median follow-up of 31.3 months after first-line treatment initiation, the median PFS was 3.3 and 20.8 months for mNCRCC and mCCRCC, respectively (p<0.0001). The median OS was 19.6 and 54.4 months for mNCRCC and mCCRCC, respectively (p<0.0001). For patients with mNCRCC, univariate Cox proportional hazards model analyses revealed that the duration of first-line treatment (p<0.0001), the time to first-line treatment within 1 year (p=0.0201), high corrected serum calcium (p=0.0006), high neutrophil count (p=0.0003), and the baseline CRP level (p=0.0034) were significantly correlated with shorter OS, respectively. Furthermore, a multivariate analysis revealed the duration of first-line treatment (Hazard ratio (HR): 0.89, 95% CI: 0.81-0.97, p=0.007), the high corrected serum calcium (HR: 4.04, 95% CI: 1.58-10.37, p=0.004), and the baseline CRP level (HR: 1.15, 95% CI: 1.05-1.25, p=0.002) were independent predictors for OS in mNCRCC patients.
Conclusions
Patients with mNCCC resulted in shorter PFS and OS. Elevated baseline C-reactive protein, a prognostic factor for mCCRCC, was also correlated with shorter OS in mNCRCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract